Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 6/20 | 0.49 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.43 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.43 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | STAT1 | P42224 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3982577 | 0.89 | MAPT (0.60) | MAPTTP53METAP2 | |
| SCHEMBL3981344 | 0.83 | METAP2 (0.56) | SLC10A2SLC10A1SLC10A6GAAMETAP2 | |
| SCHEMBL3983467 | 0.83 | TSHR (0.52) | MAPTTP53KDM4ERAB9API4KB | |
| SCHEMBL3979712 | 0.83 | TP53 (0.47) | MAPTTP53KDM4EPI4KBKMT2A | |
| SCHEMBL3986707 | 0.78 | METAP2 (0.56) | MAPTTP53RAB9APKMTSHR | |
| SCHEMBL3980654 | 0.78 | MAPT (0.56) | MAPTTP53METAP2 | |
| SCHEMBL3986148 | 0.77 | MAPT (0.58) | MAPTTP53KMT2AMEN1TSHR | |
| SCHEMBL3982957 | 0.77 | METAP2 (0.70) | MAPTTP53METAP2 | |
| SCHEMBL6704032 | 0.76 | METAP2 (0.61) | MAPTTP53METAP2 | |
| SCHEMBL4298749 | 0.75 | METAP2 (0.69) | MAPTTP53METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491718-B2 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES (US) | 2009-02-17 | — | — | US | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | MAPT 3230/4885TP53 1079/4885SLC10A2 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.